1 min read
Add as a preferred source on GoogleFDA Clears United Therapeutics for Phase 1 Trial of PAH Candidate
The open-label study will use a single ascending dose design in healthy participants and assess safety, tolerability and pharmacokinetics.
The U.S. Food and Drug Administration cleared United Therapeutics to conduct a Phase 1 trial of treprostinil-iloprost SMI, its candidate for pulmonary arterial hypertension.
The open-label study will use a single ascending dose design in healthy participants. It will assess the candidate’s safety, tolerability and pharmacokinetics.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.